93413-77-5Relevant articles and documents
Synthetic method of venlafaxine hydrochloride intermediate
-
Paragraph 0023; 0025; 0027; 0029; 0031; 0033; 0035-0036, (2021/06/02)
The invention provides a synthetic method of a venlafaxine hydrochloride intermediate, the venlafaxine hydrochloride intermediate is a compound 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol as shown in a formula I. The method comprises the following steps: carrying out hydrogenation catalytic reaction on a compound 1-cyano-(4-methoxyphenyl) methyl cyclohexanol as shown in a formula II as a raw material; and carrying out hydrogenation catalytic reaction by adopting a copper-nickel catalyst to obtain the compound as shown in the formula I. The venlafaxine hydrochloride produced by the method can effectively control the generation of impurities, and the yield and the purity of the compound shown in the formula I are improved.
Preparation method of venlafaxine impurity E (by machine translation)
-
Paragraph 0026; 0029, (2020/09/30)
The invention belongs to the technical field of organic synthesis, and relates to a preparation method of venlafaxine impurity E, which comprises (1) a condensation reaction, (2) a reduction reaction and (3) a ring-forming reaction. The method for synthesizing venlafaxine impurity E is less in steps, high in product purity, safe in reaction, less in waste liquid, simple in post-treatment, convenient to operate and convenient for industrial production. (by machine translation)
Screening of quinoline, 1,3-benzoxazine, and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis
Bharathkumar, Hanumantharayappa,Mohan, Chakrabhavi Dhananjaya,Rangappa, Shobith,Kang, Taehee,Keerthy,Fuchs, Julian E.,Kwon, Nam Hoon,Bender, Andreas,Kim, Sunghoon,Basappa,Rangappa, Kanchugarakoppal S.
, p. 9381 - 9387 (2015/09/15)
Elevated activity of methionyl-tRNA synthetase (MRS) in many cancers renders it a possible drug target in this disease area, as well as in a series of parasitic diseases. In the present work, we report the synthesis and in vitro screening of a library of 1,3-oxazines, benzoxazines and quinoline scaffolds against human MRS. Among the compounds tested, 2-(2-butyl-4-chloro-1-(4-phenoxybenzyl)-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane (compound 21) and 2-(2-butyl-4-chloro-1-(4-nitrobenzyl)-1H-imidazol-5-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine (compound 8) were found to be potent inhibitors of MRS. Additionally, these compounds significantly suppressed the proliferation of A549 and HCT116 cells with IC50 values of 28.4, 17.7, 41.9, and 19.8 μM respectively. Molecular docking studies suggested that the ligand binding orientation overlaps with the original positions of both methionine and adenosine of MRS. This suggests the binding of compound 21 against MRS, which might lead the inhibitory activity towards cancer cells.